Pak Raymond W, Moskowitz Eric J, Bagley Demetrius H
Thomas Jefferson University Hospital , Philadelphia, Pennsylvania 19107, USA.
J Endourol. 2009 Mar;23(3):341-6. doi: 10.1089/end.2008.0251.
For many years, the gold standard in upper urinary tract transitional-cell carcinoma (UT-TCC) management has been nephroureterectomy with excision of the bladder cuff. Advances in endourologic instrumentation have allowed urologists to manage this malignancy. The feasibility and success of conservative measures for UT-TCC have been widely published, but there has not been an objective cost analysis performed to date. Our goal was to examine the direct costs of renal-sparing conservative measures v nephroureterectomy and subsequent chronic kidney disease (CKD) or end-stage renal disease (ESRD). Secondary analysis includes a discussion of survival and quality-of-life issues for both treatment cohorts.
Retrospective review of a cohort of patients treated at our institution with renal-sparing ureteroscopic management of UT-TCC who were followed for a minimum of 2 years. The costs per case were based on equipment, anesthesia, surgeon fees, pathologic evaluation fees, and hospital stay. ESRD and CKD costs were estimated based on published reports.
From 1996 to 2006, 254 patients were evaluated and treated for UT-TCC at our institution. A cohort of 57 patients was examined who had a minimum follow-up period of 2 years. Renal preservation in our series approached 81%, with cancer-specific survival of 94.7%. Assuming a worst-case scenario of a solitary kidney with recurrences at each follow-up for 5 years v nephroureterectomy and dialysis for the same period, an estimated $252,272 U.S. dollars would be saved. This savings would cover the expenses of five cadaveric renal transplantations.
Conservative endoscopic management of UT-TCC in our experience should be the gold standard management for low-grade and superficial-stage disease. From a cost perspective, renal-sparing UT-TCC management is effective in reducing ESRD health care expenses.
多年来,上尿路移行细胞癌(UT-TCC)治疗的金标准一直是肾输尿管切除术并切除膀胱袖口。腔内泌尿外科器械的进步使泌尿外科医生能够处理这种恶性肿瘤。UT-TCC保守治疗措施的可行性和成功率已得到广泛报道,但迄今为止尚未进行客观的成本分析。我们的目标是研究保留肾的保守治疗措施与肾输尿管切除术及随后的慢性肾脏病(CKD)或终末期肾病(ESRD)的直接成本。次要分析包括对两个治疗队列的生存和生活质量问题的讨论。
回顾性分析在我们机构接受保留肾的输尿管镜治疗UT-TCC且随访至少2年的一组患者。每例病例的成本基于设备、麻醉、外科医生费用、病理评估费用和住院时间。ESRD和CKD成本根据已发表的报告估算。
1996年至2006年,我们机构对254例UT-TCC患者进行了评估和治疗。对一组57例患者进行了检查,其最短随访期为2年。我们系列中的肾保留率接近81%,癌症特异性生存率为94.7%。假设最坏的情况是单肾,每次随访均复发,持续5年,与同期肾输尿管切除术和透析相比,估计可节省252,272美元。这笔节省的费用将涵盖五次尸体肾移植的费用。
根据我们的经验,UT-TCC的保守内镜治疗应是低级别和浅表期疾病的金标准治疗方法。从成本角度来看,保留肾的UT-TCC治疗可有效降低ESRD的医疗费用。